Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer

Reuters01-28

Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer

Caris Life Sciences Inc. has published a new study in Nature's npj Breast Cancer journal detailing mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. The study, which analyzed real-world data from 2,799 T-DXd-treated patients, identified ERBB2 (HER2) and ABCC1 as key transcriptomic predictors of overall survival specific to T-DXd treatment. Higher ERBB2 expression was associated with improved outcomes, while higher ABCC1 expression correlated with poorer outcomes, independent of HER2 category. The research also found that increased ABCC1 expression and enrichment of mutations in ERBB2, NFE2L2, KEAP1, and TOP1 were present in post-treatment samples, suggesting routes to acquired resistance. The results of this study have already been published.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA72134) on January 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606110167?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 21:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606110167","market":"us","top_or_hot":-1,"title":"Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc. has published a new study in Nature's npj Breast Cancer journal detailing mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. The study, which analyzed real-world data from 2,799 T-DXd-treated patients, identified ERBB2 (HER2) and ABCC1 as key transcriptomic predictors of overall survival specific to T-DXd treatment. Higher ERBB2 expression was associated with improved outcomes, while higher ABCC1 expression correlated with poorer outcomes, independent of HER2 category. The research also found that increased ABCC1 expression and enrichment of mutations in ERBB2, NFE2L2, KEAP1, and TOP1 were present in post-treatment samples, suggesting routes to acquired resistance. The results of this study have already been published.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA72134) on January 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCaris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 21:31</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Caris Life Sciences Inc. has published a new study in Nature's npj Breast Cancer journal detailing mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. The study, which analyzed real-world data from 2,799 T-DXd-treated patients, identified ERBB2 (HER2) and ABCC1 as key transcriptomic predictors of overall survival specific to T-DXd treatment. Higher ERBB2 expression was associated with improved outcomes, while higher ABCC1 expression correlated with poorer outcomes, independent of HER2 category. The research also found that increased ABCC1 expression and enrichment of mutations in ERBB2, NFE2L2, KEAP1, and TOP1 were present in post-treatment samples, suggesting routes to acquired resistance. The results of this study have already been published.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA72134) on January 28, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4104","symbol_name":"贸易公司与经销商","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL8B5W6P:1","article_id":"2606110167","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606110167","pubTimestamp":1769607086,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Caris Life Sciences Inc. has published a new study in Nature's npj Breast Cancer journal detailing mechanisms of resistance to trastuzumab deruxtecan  in metastatic breast cancer. The study, which analyzed real-world data from 2,799 T-DXd-treated patients, identified ERBB2  and ABCC1 as key transcriptomic predictors of overall survival specific to T-DXd treatment. Higher ERBB2 expression was associated with improved outcomes, while higher ABCC1 expression correlated with poorer outcomes, independent of HER2 category. The research also found that increased ABCC1 expression and enrichment of mutations in ERBB2, NFE2L2, KEAP1, and TOP1 were present in post-treatment samples, suggesting routes to acquired resistance. The results of this study have already been published.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4104":"贸易公司与经销商","BK4139":"生物科技","CAI":"Caris Life Sciences, Inc."},"translate_title":"Caris Life Sciences确定了转移性乳腺癌对曲妥珠单抗Deruxtecan的关键耐药机制","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAI":0.9},"content_text":"Caris Life Sciences Identifies Key Resistance Mechanisms to Trastuzumab Deruxtecan in Metastatic Breast Cancer\n    \n\n        Caris Life Sciences Inc. has published a new study in Nature's npj Breast Cancer journal detailing mechanisms of resistance to trastuzumab deruxtecan (T-DXd) in metastatic breast cancer. The study, which analyzed real-world data from 2,799 T-DXd-treated patients, identified ERBB2 (HER2) and ABCC1 as key transcriptomic predictors of overall survival specific to T-DXd treatment. Higher ERBB2 expression was associated with improved outcomes, while higher ABCC1 expression correlated with poorer outcomes, independent of HER2 category. The research also found that increased ABCC1 expression and enrichment of mutations in ERBB2, NFE2L2, KEAP1, and TOP1 were present in post-treatment samples, suggesting routes to acquired resistance. The results of this study have already been published.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA72134) on January 28, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606110167","isCrawlerRequest":true}